Core Insights - RxSight, Inc. reported a decrease in total revenue for the fiscal year 2025, with global sales of $134.5 million, down 4% from the previous year, primarily due to a significant drop in Light Delivery Device (LDD) system sales, which decreased by 48% compared to 2024 [4][6] - The company experienced a 12% growth in Light Adjustable Lens (LAL) revenue, indicating strong adoption among physicians and patients [4][6] - Operating expenses increased by 11% to $151.2 million, driven by strategic investments in commercial and operational expansion, as well as research and development [5][6] Financial Performance - For the fourth quarter of 2025, total revenue was $32.6 million, a 19% decrease from $40.2 million in Q4 2024, largely due to lower LDD revenue [7][11] - Gross profit for the fourth quarter was $25.3 million, representing 77.5% of revenue, a decrease from 71.6% in the same quarter of the previous year [8] - The net loss for the full year 2025 was $(38.9) million, or $(0.95) per share, compared to a net loss of $(27.5) million, or $(0.71) per share in 2024 [6][11] Unit Sales and Market Position - In 2025, unit sales of LAL increased by 12% to 109,615, while LDD unit sales dropped by 47% [9][12] - The installed base of LDD expanded to 1,134, providing a foundation for future procedure growth [9] - Over 300,000 RxSight LAL procedures have been performed since the product launch, highlighting its clinical benefits [9] Strategic Developments - The company has received regulatory approvals for the RxSight system in multiple regions, including North America, Europe, Singapore, South Korea, and Australia, enhancing its international market opportunities [5][9] - RxSight's FDA post-approval study results demonstrating superior outcomes for LAL eyes compared to traditional toric IOLs have been accepted for publication, reinforcing the product's clinical value [9] 2026 Financial Guidance - The company provided guidance for 2026, projecting revenue between $120.0 million and $135.0 million, with expected gross margins of 70% to 72% [16]

Core Viewpoint - RxSight, Inc. has announced preliminary unaudited financial and operational results for Q4 and full-year 2025, indicating a positive trajectory in patient treatment and market share despite challenges faced during the year [1][3][8]. Financial Results - Preliminary unaudited revenue for Q4 2025 is expected to be approximately $32.6 million, driven by the sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®), representing a 10% increase in procedure volume compared to Q3 2025 [8]. - Preliminary unaudited revenue for the full year 2025 is expected to be approximately $134.5 million, exceeding previous guidance of $125 to $130 million, with a 12% increase in procedure volume compared to 2024 [8]. - The company installed 1,134 Light Delivery Devices (LDDs) by the end of 2025, with a total of 163 LDDs sold during the year [8]. Market Position and Growth - RxSight holds approximately 10% market share in the premium intraocular lens (IOL) market, with adoption by over 25% of U.S. cataract surgeons [3]. - The company has made significant progress in treating more patients than ever before, positioning itself for sustained long-term growth [3]. Leadership Transition - Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience [4][5]. - Wilterding's previous role was Senior Vice President of Global Finance for Edwards Lifesciences, where he oversaw various financial operations [5]. Future Outlook - The company is set to announce audited full-year 2025 financial results and guidance for 2026 in February 2026 [7][8].

Core Insights - RxSight, Inc. reported a total revenue of $33.6 million for Q2 2025, a 4% decrease from $34.9 million in Q2 2024, with LAL revenue increasing by 13% and LDD revenue decreasing by 50% [4][10] - The company aims to accelerate growth through enhanced customer engagement and strategic expansion of its installed base, supported by a newly launched Customer Success Organization [3] Financial Performance - Gross profit for Q2 2025 was $25.2 million, representing 74.9% of revenue, an increase from $24.3 million or 69.5% of revenue in Q2 2024 [5] - Total operating expenses for Q2 2025 were $39.2 million, a 20% increase from $32.6 million in Q2 2024, reflecting investments in LAL sales and R&D [6] - The net loss for Q2 2025 was $(11.8) million, or $(0.29) per share, compared to a net loss of $(6.1) million, or $(0.16) per share in Q2 2024 [7] Cash Position - Cash, cash equivalents, and short-term investments decreased by $1.8 million to $227.5 million as of June 30, 2025, compared to $229.3 million as of March 31, 2025 [8] Guidance - The company reiterated its 2025 full-year revenue guidance of $120.0 million to $130.0 million, indicating a decrease of 14% to 7% compared to 2024 [9][14]

Core Viewpoint - RxSight, Inc. has announced preliminary financial results for Q2 2025, indicating a decrease in revenue and a revised full-year guidance, while also focusing on enhancing customer success and engagement with clinical partners [1][3]. Preliminary Second Quarter 2025 Results - Preliminary revenue for Q2 2025 is expected to be approximately $33.6 million, a decrease of 4% year-over-year and an 11% decrease compared to Q1 2025 [8]. - The company sold 27,380 Light Adjustable Lenses (LAL®/LAL+®), reflecting a 1% decrease in procedure volume from Q1 2025 but a 13% increase from Q2 2024 [8]. - The sale of 40 Light Delivery Devices (LDD™s) saw a significant decline, with a 45% decrease compared to Q1 2025 and a 49% decrease compared to Q2 2024 [8]. - As of June 30, 2025, the installed base of LDDs increased to 1,084, a 34% growth from 810 LDDs at the end of Q2 2024 [8]. Revised 2025 Guidance - Full-year revenue guidance has been revised downward to a range of $120.0 million to $130.0 million, a decrease from the previous range of $160.0 million to $175.0 million, implying a decrease of 14% to 7% compared to 2024 [9]. - Gross margin guidance has been increased to a range of 72% to 74%, up from the previous range of 71% to 73%, representing an increase of 130 to 330 basis points compared to 2024 [9]. - Operating expense guidance is set between $145.0 million and $155.0 million, indicating an increase of 7% to 14% compared to 2024, which includes non-cash stock-based compensation expenses estimated between $27.0 million and $30.0 million [9].

Core Insights - RxSight, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $37.9 million, a 28% increase from $29.5 million in Q1 2024, driven by significant growth in Light Adjustable Lens (LAL) sales [4][9] - The company continues to emphasize the clinical value of its Light Adjustable Lens, which is gaining traction among cataract surgeons, and believes that customization and post-operative adjustability will be key trends in premium cataract surgery [3][9] Financial Performance - Total revenue for Q1 2025 was $37.9 million, up 28% from $29.5 million in Q1 2024, with LAL revenue increasing by 37% and Light Delivery Device (LDD) revenue rising by 8% [4][9] - Gross profit for Q1 2025 was $28.3 million, representing 74.8% of revenue, an increase from $20.7 million or 70.1% of revenue in Q1 2024, attributed to lower cost of sales and a favorable product mix [5][9] - Operating expenses for Q1 2025 totaled $39.0 million, a 24% increase from $31.4 million in Q1 2024, reflecting investments in LDD and R&D [6][9] - The net loss for Q1 2025 was $(8.2) million, or $(0.20) per share, an improvement from a net loss of $(9.1) million, or $(0.25) per share in Q1 2024 [7][9] Guidance and Market Position - The company reiterated its full-year 2025 revenue guidance of $160.0 million to $175.0 million, indicating growth of 14% to 25% compared to 2024 [10] - Gross margin is expected to be in the range of 71% to 73%, while operating expenses are projected to be between $150.0 million and $160.0 million, reflecting a 10% to 18% increase compared to 2024 [10][11] - RxSight sold 27,579 LALs in Q1 2025, a 36% increase in procedure volume compared to the same period in 2024, and expanded its installed base of LDDs to 1,044, a 43% increase year-over-year [9][10]